On January 17, Xinhua Pharmaceutical announced that its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Co.
("Xinda Pharmaceutical") received the "Approval Notice for Supplementary Drug Application" for pioglitazone hydrochloride capsules approved and issued by the State Food and Drug Administration.
, the product consistency evaluation application was approved
Xinda Pharmaceutical is the first company in China to pass the consistency evaluation of pioglitazone hydrochloride capsules
Pioglitazone hydrochloride was developed by Takeda Corporation of Japan.
It was first listed in the United States in July 1999.
It is mainly used for the treatment of type 2 diabetes.
It has been listed in Australia, Canada, Japan, Germany, Denmark, Spain and other countries and is widely used
Relevant data show that in the past three years, the sales of pioglitazone hydrochloride tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have remained above 500 million yuan